Search Results
Your search for Andrew D. Zelenetz, MD, PhD matches 11 pages
Showing 1 - 11
Andrew D. Zelenetz, MD, PhD, and Michael L. Wang, MD, on Mantle Cell Lymphoma: New Data on Ibrutinib in Combination With Bendamustine/Rituximab and Rituximab Maintenance
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Michael L. Wang, MD, of The University of Texas MD Anderson Cancer Center, discuss primary results from the phase III SHINE study, which showed that ibrutinib, in combination with bendamustine/rituximab and rituximab...
Andrew D. Zelenetz, MD, PhD, on MRD Testing in the Management of Non-Hodgkin Lymphoma
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the role of minimal residual disease evaluation in the treatment of non-Hodgkin lymphoma, techniques used to predict relapse such as immunosequencing and CAPP-Sequencing, and whether such assays could replace the use...
Andrew D. Zelenetz, MD, PhD, on Mantle Cell Lymphoma: Expert Perspective on Key Clinical Trials
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, offers his expert views on five treatment studies in mantle cell lymphoma focusing on the next-generation BTK inhibitor LOXO-305; lisocabtagene maraleucel; minimal residual disease monitoring following autologous stem cell...
Andrew D. Zelenetz, MD, PhD, on Mantle Cell Lymphoma: Immunochemotherapy Plus Lenalidomide
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses phase II results from a single-center study that explored a novel approach for high-risk patients with mantle cell lymphoma. Among patients with TP53 wild-type disease, the data suggested this treatment was effective...
Andrew D. Zelenetz, MD, PhD, on NHL: Clinical Applications of Genomic Studies
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the various ways genomics can be used in diagnosing and treating non-Hodgkin lymphoma and the need for a proper support tool to help interpret the data.
Andrew D. Zelenetz, MD, PhD, and Sattva S. Neelapu, MD, on NHL: Results From the ZUMA-1 Trial
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Sattva S. Neelapu, MD, of The University of Texas MD Anderson Cancer Center, discuss long-term study findings on axicabtagene ciloleucel in patients with refractory aggressive non-Hodgkin lymphoma (Abstract 578).
Andrew D. Zelenetz, MD, PhD, and Stephen J. Schuster, MD, on DLBCL: Results of the JULIET Trial
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Stephen J. Schuster, MD, of the Abramson Cancer Center, University of Pennsylvania, discuss phase II findings on tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma (Abstract 577).
Electronic Health Record Data May Help Identify Older Patients at Highest Risk of Early Death From Chemotherapy for Diffuse Large B-Cell Lymphoma
Although diffuse large B-cell lymphoma (DLBCL) is a curable disease in most patients aged 65 years or older, these patients are also at higher risk of chemotherapy-related death within the first 30 days of treatment. To quantify the risk of early fatality and identify risk factors, researchers led ...
Sagar Lonial, MD, and Andrew Zelenetz, MD, PhD, on MCL, DLBCL, CLL: How Much Rituximab Is Enough?
Sagar Lonial, MD, of Emory University School of Medicine, and Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss newly reported findings on rituximab maintenance therapy in hematologic malignancies (Abstracts 7503, 7504, and 7505).
Andrew D. Zelenetz, MD, PhD, on Emerging Treatment Options for Lymphomas
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, talks about the revolution in lymphoma treatment, which started with rituximab and continues with obinutuzumab, ibrutinib, and others.
Erratum
In the June 10 issue of The ASCO Post, the article, “Study Questions Routine Use of Imaging after Treatment for Diffuse Large B-cell Lymphoma,” includes an error in an Expert Point of View box featuring an interview with Andrew D. Zelenetz, MD, PhD. Dr. Zelenetz is quoted as saying that at his...
